Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
anthelmintic drug
|
| gptkbp:affiliatedWith |
benzimidazole
|
| gptkbp:approvalYear |
1996
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
P02CA03
|
| gptkbp:brand |
gptkb:Zentel
gptkb:Albenza gptkb:Andazol gptkb:Eskazole gptkb:Valbazen |
| gptkbp:CASNumber |
54965-21-8
|
| gptkbp:chemicalFormula |
C12H15N3O2S
|
| gptkbp:contraindication |
pregnancy
known hypersensitivity |
| gptkbp:developedBy |
1975
|
| gptkbp:discoveredBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
8.5 hours
|
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
Albendazole
|
| gptkbp:includedIn |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds to beta-tubulin
inhibits microtubule polymerization |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
265.33 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
2082
DB00518 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting abdominal pain dizziness headache hair loss elevated liver enzymes bone marrow suppression |
| gptkbp:UNII |
F4216019LN
|
| gptkbp:usedFor |
treatment of strongyloidiasis
treatment of ascariasis treatment of cutaneous larva migrans treatment of filariasis treatment of giardiasis treatment of hookworm infection treatment of hydatid disease treatment of neurocysticercosis treatment of parasitic worm infestations treatment of trichuriasis treatment of enterobiasis |
| gptkbp:bfsParent |
gptkb:Tapeworm
|
| gptkbp:bfsLayer |
6
|